Product Name
CAS Number
Specification
TP
DMF
Status
Fedratinib
936091-26-8
Q4 2025
Q2 2026
Finerenone
1050477-31-0
Q4 2025
Q2 2026
Fluvastatin sodium
93957-55-2
CP, USP, EP, JP
√
Galanthamine
357-70-0
EP, In-house
Q3 2025
Gilteritinib
1254053-43-4
Q4 2025
Q2 2026
Imatinib Mesylate
220127-57-1
EP, In-house
√
Inavolisib
2060571-02-8
Q4 2025
Q2 2026
Ivacaftor
873054-44-5
Q3 2025
Q1 2026
Lactulose
4618-18-2
Q42025
Q1 2026
Lanreotide acetate
127984-74-1
Lapatinib
231277-92-9
Q4 2025
Q2 2026
Latanoprost
130209-82-4
USP, EP
√
Lenvatinib Mesylate
857890-39-2
In-house
√
Lifitegrast
1025967-78-5
Q4 2025
Q2 2026
Limaprost
74397-12-9
Q4 2025
Q2 2026
Linaclotide
851199-59-2
Liraglutide
204656-20-2
Lixisenatide
320367-13-3
Lorlatinib
1454846-35-5
Q3 2025
Q1 2026
Lotilaner
1369852-71-0
Q4 2025
Q2 2026